Aug 2026· Proceedings of the 32nd ACM SIGKDD Conference on Knowledge Discovery and Data Mining V.2· pp. 11236-11247· 0 citations· 33 references
TL;DR
DiffPro, a novel framework that integrates a Latent Diffusion Model (LDM) as a structural prior, confirms that the diffusion prior successfully regularizes the latent space, mitigating task representation collapse and enabling robust, high-precision predictions for combination therapy design.
Abstract
Predicting drug synergy is essential for optimizing combination therapies in cancer treatment. Under extreme data scarcity, existing computational methods struggle to generalize to new cell lines. Although meta-learning approaches have shown promise, a critical limitation lies in their reliance on a unimodal Gaussian prior for task representation. In extreme few-shot settings, this assumption can overly pull the task posterior toward the prior mean, reducing the discriminability of task representations and pushing the model toward a generic mean-value predictor. To overcome this, we propose DiffPro, a novel framework that integrates a Latent Diffusion Model (LDM) as a structural prior. Unlike Gaussian-based methods, our diffusion module learns a flexible, data-driven prior that can model highly complex task distributions. This learned prior better reflects task heterogeneity in few-shot drug synergy prediction under extreme data scarcity, yielding more discriminative task representations. Comprehensive experiments on the DrugComb dataset demonstrate that DiffPro achieves a significant improvement in performance. Notably, in the challenging 5-shot setting, it outperforms the best-performing baseline, delivering approximately a 17.3% relative gain in R2 (0.264 vs. 0.225) and a 4.6% relative reduction in MSE. These results confirm that the diffusion prior successfully regularizes the latent space, mitigating task representation collapse and enabling robust, high-precision predictions for combination therapy design.
Overall, scLDM provides a robust and biologically consistent strategy for in silico perturbation screening, and exhibits strong interpretability, as the learned perturbation embeddings show high functional alignment with known biological mechanisms.
HSSynergy, a hierarchical substructure-aware deep learning framework for predicting anticancer drug synergy, introduces a Scale-Aware Masked Attention mechanism that enforces precise layer-wise alignment, and utilizes hierarchical grouping with mask constraints to achieves same-scale focusing while shielding against cr...
Yue-Hua Feng, Shu-Cong Zhang, Xiao-Ying Yan et al.· Journal of Cheminformatics· 0 citations
Drug repositioning has emerged as an attractive drug development strategy with deep learning-based computational methods showing great potential in predicting Drug-Disease Associations (DDAs). However, dominant computational paradigms typically rely on Random Negative Sampling (RNS) and static embedding fusion, leading...
Ke-Rui Xu, Ke-Yuan Xu, Shu-Hui Yin et al.· Proceedings of the Thirty-Fi...· 0 citations
MKASynergy, an adaptive drug synergy prediction method based on a mixture-of-experts kernel mechanism, achieves competitive predictive performance and visualization analysis confirms the model’s effectiveness in feature decoupling and helps interpret latent drug synergistic mechanisms.
Cundong Lin, Jiancheng Ni, Ying Yang et al.· Network Modeling Analysis in...· 0 citations
CaMeRe, a Causally-inspired Meta-representation learning framework designed to predict patient-specific clinical Response to drug combinations, exhibited robust multi-domain generalization performance across multiple clinical drug combination response datasets and PDXs drug combination response datasets and generalizat...
Qing-Qing Zhang, Shao-Wu Zhang, Ming-Hui Shi et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.